SAVA
Cassava Sciences Inc
$24.12
Earnings Summary
Revenue | $0Mn |
Net Profits | $-9.56Mn |
Net Profit Margins | -Inf% |
Highlights
Cassava Sciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2021. On a quarterly growth basis, Cassava Sciences Inc has generated NaN% jump in its revenue since last 3-months.
Cassava Sciences Inc’s net profit fell -568.67% since last year same period to $-9.56Mn in the Q3 2021. On a quarterly growth basis, Cassava Sciences Inc has generated -86.58% fall in its net profits since last 3-months.
Cassava Sciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2021. On a quarterly growth basis, Cassava Sciences Inc has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Cassava Sciences Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Current Year | -0.54 |
Highlights
Cassava Sciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.54 - a -12.5% fall from last quarter’s estimates.
Cassava Sciences Inc’s earning per share (EPS) estimates for the current year stand at -0.54.
Key Ratios
Key ratios of the Cassava Sciences Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.2 |
Return on Equity (ROE) | -0.32 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cassava Sciences Inc’s return on assets (ROA) stands at -0.2.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cassava Sciences Inc’s return on equity (ROE) stands at -0.32.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2016-05-05 | -0.7 | -0.91 | -30% |
2016-10-26 | -0.63 | -0.56 | 11.11% |
2017-03-07 | -0.56 | -0.42 | 25% |
2016-07-19 | -0.98 | -0.49 | 50% |
Company Information
Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.
Organisation | Cassava Sciences Inc |
Headquarters | 7801 North Capital of Texas Highway, Austin, TX, United States, 78731 |
Employees | 26 |
Industry | Pharmaceuticals: Other |
CEO | Remi Barbier |
